logo

Sanofi (SNY)



Trade SNY now with
  Date
  Headline
1/27/2023 8:38:41 AM Regeneron : Dupixent Recommended For EU Approval To Treat Children With Severe Atopic Dermatitis
12/21/2022 7:25:18 PM Regeneron : Positive Dupixent Phase 3 Results In Adults &Adolescents With Eosinophilic Esophagitis Published
12/19/2022 1:03:32 AM Sanofi, Innate Pharma Expand Collaboration For Natural Killer Cell Therapeutics In Oncology
12/16/2022 7:32:45 AM Regeneron : Dupixent Recommended For EU Approval By CHMP For Treatment Of Eosinophilic Esophagitis
12/15/2022 1:03:14 AM Regeneron Pharma, Sanofi: EC Expands Marketing Authorization For Dupixent In The European Union For Prurigo Nodularis
11/11/2022 7:00:59 AM Regeneron Pharma And Sanofi Announce Dupixent Recommended For EU Approval By The CHMP For Prurigo Nodularis
10/28/2022 1:37:33 AM Sanofi Q3 Business EPS EUR 2.88; IFRS EPS EUR 1.66